ClinicalTrials.gg
CompletedNCT02285062ROBUSTUpdated Jun 22, 2023Results posted

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

A Phase 3 interventional study of lenalidomide and Placebo in Lymphoma, Large B-Cell, Diffuse, sponsored by Celgene. Completed at 158 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse — 14 open to participants now, 29 under way, 4 of them phase 3. Lenalidomide · Lymphoma, Large B-Cell, Diffuse.

Enrollment
3rd of 70
570 · median 55
Started
2015
with 2 others
Phase 3
7 of 71
1 open now
Registered
25th of 71
by date
Lead sponsor
2 of 71
Celgene

Among the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, this one is the 3rd largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2015, is one of 7 in phase 3, and was the 25th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

14 of the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse are open now, in 4 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.

Read the detailed description

This research study is for patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL) of the activated B-cell (ABC) type who have not yet been treated. DLBCL is a cancer of a type of blood cell called B-lymphocytes. B lymphocytes are part of the body's immune system. There are different types of DLBCL. About a third of newly diagnosed DLBCL cancers are the ABC type. It has been observed that treatment does not work as well for patients with the ABC type compared to patients with other DLBCL types who receive standard treatment. However, at this time both ABC type and other DLBCL type patients receive the same standard treatments.

Patients with DLBCL who are otherwise healthy are usually treated first with the chemotherapy drug combination called R-CHOP. The drugs in this combination are "R" for rituximab, "C" for cyclophosphamide, "H" for doxorubicin which has a chemical name of hydroxydaunomycin, "O" for vincristine which has a trade name of oncovin, and "P" for prednisone. Depending on the local practice where you are treated, R-CHOP may be given for 6 or 8 cycles. A cycle could lasts for 14 or 21 days. The R-CHOP drug combination is approved for the treatment of DLBCL of all types, including ABC type. R-CHOP is standard care.

This study will test the standard R-CHOP21 against R-CHOP21 plus lenalidomide. The purpose is to see whether adding lenalidomide works better and is as safe as R-CHOP by itself. This study is only for patients with ABC type DLBCL who have not yet been treated. Lenalidomide is not approved for use in DLBCL. Its use in this disease is experimental. In this study, the experimental treatment is lenalidomide + R-CHOP21 x 6.

This study will use a gene expression profile (GEP) test to see if a patient has the ABC type. The results of this GEP test affect whether you may be treated on this study. Because the performance of this test has not been proven, it is for investigational use only, and is still under development. This means the GEP test is an experimental test.

03

Conditions studied

  • Lymphoma, Large B-Cell, Diffuse

Keywords

  • R-CHOP chemotherapy
  • DLBCL front line therapy
  • gene expression profiling (GEP) activated B-cell (ABC) type DLBCL biomarkers
  • Activated B-Cell (ABC) type
  • Diffuse Large B-Cell Lymphoma, not otherwise specified
  • Diffuse Large B-Cell Lymphoma, associated with chronic inflammation
  • Diffuse Large B-Cell Lymphoma, Epstein-Barr virus positive (EBS+) of the elderly
  • Diffuse Large B-Cell Lymphoma, T-cell / histiocyte-rich
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven Diffuse Large B-Cell Lymphoma of the Activated B-Cell type
  2. Newly diagnosed, previously untreated Diffuse Large B-Cell Lymphoma
  3. Measurable Diffuse Large B-Cell Lymphoma disease by Computed Tomography (CT) / Magnetic Resonance Imagining (MRI) scans
  4. (ECOG) performance status 0 - 2
  5. Age 18 - 80 years; age > 80 allowed at investigator discretion if performance status ≤ 1; and each organ system score ≤ 2 using cumulative illness rating scale (CIRS)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of lymphoma histologies other than Diffuse Large B-Cell Lymphoma
  2. History of , other than Diffuse Large B-Cell Lymphoma, unless the patient has been disease free for 5 years or more
  3. Known seropositive for, or history of, active (HIV) Virus (HBV), Virus (HCV)
  4. to any drug in the chemotherapy regimen, and specifically: (Left Ventricular Ejection Fraction) \< 45% or peripheral neuropathy grade 2
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
570 participants (actual)

Study arms

  • Experimental
    R2-CHOP

    Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)

    Drug: lenalidomide · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: prednisone · Drug: vincristine

  • Active comparator
    R-CHOP

    Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)

    Drug: Placebo · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: prednisone · Drug: vincristine

Interventions

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimate of Progression Free Survival (PFS)

    Progression free survival was defined as the time (months) from the date of randomization to the date of disease progression or death (any cause), whichever occurred earlier and was assessed by the Independent Response Adjudication Committee (IRAC). Relapse from complete response (CR) was considered as disease progression throughout the study. Disease progression was determined based on the Revised Response Criteria for Malignant Lymphoma. The PFS analysis was based on the censoring rules using the Food and Drug Administration (FDA) Guidance. Participants who did not experience disease progression and who did not die before the clinical data cutoff date were censored at the date of last adequate response assessment.

    Time frame: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months

Secondary outcomes

  1. Kaplan-Meier (K-M) Estimate of Event Free Survival (EFS)

    EFS was defined as the time (months) from randomization until occurrence of one of the following events, whichever occurred first: • Disease progression • Initiation of subsequent systemic anti-lymphoma therapy • Death due to any cause The assessment of EFS was conducted by the IRAC using the International Working Group (IWG) criteria for NHL. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as an EFS event (initiation of subsequent systemic anti-lymphoma therapy) if the decision to treat and the location to be treated was determined prior to randomization. Participants who did not experience any of the events defined in the categories above before the clinical data cutoff date were censored at date last known alive.

    Time frame: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up was 24.5 months

  2. K-M Estimate of Overall Survival (OS)

    Overall survival was assessed by the Independent Response Adjudication Committee (IRAC) and defined as time from randomization until death due to any cause. Participants who withdrew consent were censored at the time of withdrawal. Participants who were still alive before the clinical data cutoff date and participants who were lost to follow-up were censored at date last known alive.

    Time frame: From randomization until death due to any cause (up to approximately 86 months)

  3. Percentage of Participants Who Achieved a Complete Response (CR)

    The percentage of participants who achieved a CR after initiation of the study treatment and prior to initiation of subsequent systemic antilymphoma therapy as assessed by the IRAC. A CR = complete metabolic response; target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow per International Working Group (IWG) 2014 for Non-Hodgkin's Lymphoma (NHL). Participants who did not have any adequate response assessments during this period were not considered as responders.

    Time frame: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months

  4. Percentage of Participants Who Achieved an Objective Response

    An objective response = percentage of participants who achieved a complete response or partial response after initiation of the treatment and prior to initiation of subsequent systemic anti-lymphoma therapy. A CR = complete metabolic response; Target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter; no new lesions. Participants who did not have any adequate response assessments during this period were not considered as responders.

    Time frame: From randomization date up to the data cut off date of 15 March 2019; median total treatment duration was 18.10 weeks for both treatment arms; range = 1.6 to 29.0 weeks for R2-CHOP arm and 0.3 to 22.9 weeks for placebo-R-CHOP arm

  5. K-M Estimate of Duration of Complete Response

    Duration of complete response was calculated for complete responders only and was defined as the time from documented initial complete response prior to initiation of subsequent systemic antilymphoma therapy until documented disease progression or death, whichever occurred earlier. Participants who had not progressed or died at the time of the analysis were censored at the date of last response assessment demonstrating no disease progression. Participants who changed treatment without evidence of disease progression were censored at the last assessment showing no progression prior to treatment change.

    Time frame: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months.

  6. K-M Estimate of Time to Next Lymphoma Therapy (TTNLT)

    Time to next lymphoma therapy was defined as the time from randomization to the time of treatment change for the next lymphoma treatment. Participants without treatment change were censored at date last known alive. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as treatment change for the next lymphoma therapy if the decision to treat and the location to be treated were determined prior to randomization.

    Time frame: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months

  7. Percentage of Participants Who Completed the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire

    The completion rate for FACT-Lym assessments was judged by looking at the number of completed FACT-Lym assessments at each time point. The FACT-Lym was considered completed if at least 1 calculable score was present. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The FACT-Lym is a health related quality of life (HRQoL) questionnaire targeted to the management of chronic illness, predominantly within oncology and is considered an extension of the FACT-General questionnaire.

    Time frame: Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

  8. Percentage of Participants Who Completed the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Health Related Quality of Life (HR-QoL) Questionnaire

    The completion rate for EQ-5D assessments was judged by looking at the number of completed assessments at each time point. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored using the United Kingdom (UK) index ranges from -0.594 - 1, where 0 equates to death and 1 equates to full health -0.594 is considered 'worse than death'.

    Time frame: Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

  9. Mean Change From Baseline in the FACT-Lym Physical Well-Being Subscale

    The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The physical well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.

    Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

  10. Mean Change From Baseline in the FACT-Lym Additional Concerns Subscale

    The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms such as pain, itching, night sweats,trouble sleeping, fatigue and trouble concentrating and concerns regarding lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The Additional Concerns subscale ranges from 0 to 60, where higher scores reflect better HRQoL.

    Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

  11. Mean Change From Baseline in the FACT-Lym Functional Well-Being Subscale

    The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The functional well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.

    Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

  12. Mean Change From Baseline in the FACT-Lym Trial Outcome Index (TOI)

    The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The FACT-Lym TOI is calculated by summing the Physical Well-being, Functional Well-being and Additional Concerns scores and has a range of 0 to 116. Higher scores reflect better HRQoL or fewer symptoms.

    Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

  13. Mean Change From Baseline in the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Index Score

    The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored as a single summary index using one of the available EQ-5D-3L value sets; in this study the UK scoring weights 9 were used. The UK index ranges from -0.594 to 1, where 0 equates to death and 1 equates to full health (-0.594 is considered 'worse than death').

    Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

  14. Mean Change From Baseline in the EQ-5D-3L Visual Analogue Scale (VAS)

    The EQ-5D-3L questionnaire includes a visual analogue scale which records the respondent's self-rated health on a vertical, 0-100 scale where 100 = "Best imaginable health state" and 0 = "Worst imaginable health state". Higher scores again indicate better HRQoL and positive change scores indicate that post screening values were higher than those observed at screening. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems".

    Time frame: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

07

Results

Posted Mar 30, 2020

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestoneLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Started285285
Completed284283
Not completed12
Withdrew: Protocol violation02
Withdrew: Participant withdrew consent10
Treatment Period
Participant flow — Treatment Period
MilestoneLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Started283284
Completed211240
Not completed7244

Outcome measures

PrimaryKaplan-Meier Estimate of Progression Free Survival (PFS)

Progression free survival was defined as the time (months) from the date of randomization to the date of disease progression or death (any cause), whichever occurred earlier and was assessed by the Independent Response Adjudication Committee (IRAC). Relapse from complete response (CR) was considered as disease progression throughout the study. Disease progression was determined based on the Revised Response Criteria for Malignant Lymphoma. The PFS analysis was based on the censoring rules using the Food and Drug Administration (FDA) Guidance. Participants who did not experience disease progression and who did not die before the clinical data cutoff date were censored at the date of last adequate response assessment.

Time frame:
From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months
Reported as:
Median · months
Kaplan-Meier Estimate of Progression Free Survival (PFS)
monthsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Kaplan-Meier Estimate of Progression Free Survival (PFS)NA (NA to NA)NA (35.5 to NA)
Statistical analysis
  • Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP · Log Rank · p = 0.2864 · Hazard ratio (hr): 0.849 · 95% CI 0.632 to 1.140Hazard ratio was derived from Cox proportional hazard model adjusting for the 3 stratification factors
SecondaryKaplan-Meier (K-M) Estimate of Event Free Survival (EFS)

EFS was defined as the time (months) from randomization until occurrence of one of the following events, whichever occurred first: • Disease progression • Initiation of subsequent systemic anti-lymphoma therapy • Death due to any cause The assessment of EFS was conducted by the IRAC using the International Working Group (IWG) criteria for NHL. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as an EFS event (initiation of subsequent systemic anti-lymphoma therapy) if the decision to treat and the location to be treated was determined prior to randomization. Participants who did not experience any of the events defined in the categories above before the clinical data cutoff date were censored at date last known alive.

Time frame:
From the date of randomization up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
Reported as:
Median · Months
Kaplan-Meier (K-M) Estimate of Event Free Survival (EFS)
MonthsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Kaplan-Meier (K-M) Estimate of Event Free Survival (EFS)NA (NA to NA)NA (31.3 to NA)
Statistical analysis
  • Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP · Log Rank · p = 0.7294 · Hazard ratio (hr): 1.038 · 95% CI 0.802 to 1.344Hazard ratio was derived from Cox proportional hazard model adjusting for the 3 stratification factors.
SecondaryK-M Estimate of Overall Survival (OS)

Overall survival was assessed by the Independent Response Adjudication Committee (IRAC) and defined as time from randomization until death due to any cause. Participants who withdrew consent were censored at the time of withdrawal. Participants who were still alive before the clinical data cutoff date and participants who were lost to follow-up were censored at date last known alive.

Time frame:
From randomization until death due to any cause (up to approximately 86 months)
Reported as:
Median · Months
K-M Estimate of Overall Survival (OS)
MonthsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
K-M Estimate of Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP · Log Rank · p = 0.8760 · Hazard ratio (hr): 0.965 · 95% CI 0.716 to 1.300Hazard ratio was derived from Cox proportional hazard model adjusting for the 3 stratification factors.
SecondaryPercentage of Participants Who Achieved a Complete Response (CR)

The percentage of participants who achieved a CR after initiation of the study treatment and prior to initiation of subsequent systemic antilymphoma therapy as assessed by the IRAC. A CR = complete metabolic response; target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow per International Working Group (IWG) 2014 for Non-Hodgkin's Lymphoma (NHL). Participants who did not have any adequate response assessments during this period were not considered as responders.

Time frame:
From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a Complete Response (CR)
Percentage of ParticipantsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Percentage of Participants Who Achieved a Complete Response (CR)69.1 (63.4 to 74.4)64.9 (59.1 to 70.4)
Statistical analysis
  • Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP · Cochran-Mantel-Haenszel · p = 0.2933 (Obtained from CMH test adjusting for stratification factors: IPI score (2 or ≥ 3), presence of bulky disease (bulky or nonbulky), and age (\< 65 or ≥ 65))
SecondaryPercentage of Participants Who Achieved an Objective Response

An objective response = percentage of participants who achieved a complete response or partial response after initiation of the treatment and prior to initiation of subsequent systemic anti-lymphoma therapy. A CR = complete metabolic response; Target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter; no new lesions. Participants who did not have any adequate response assessments during this period were not considered as responders.

Time frame:
From randomization date up to the data cut off date of 15 March 2019; median total treatment duration was 18.10 weeks for both treatment arms; range = 1.6 to 29.0 weeks for R2-CHOP arm and 0.3 to 22.9 weeks for placebo-R-CHOP arm
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an Objective Response
Percentage of ParticipantsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Percentage of Participants Who Achieved an Objective Response90.9 (86.9 to 94.0)90.9 (86.9 to 94.0)
Statistical analysis
  • Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP · Cochran-Mantel-Haenszel · p = 0.9964 (Obtained from CMH test adjusting for stratification factors: IPI score (2 or ≥ 3), presence of bulky disease (bulky or nonbulky), and age (\< 65 or ≥ 65))
SecondaryK-M Estimate of Duration of Complete Response

Duration of complete response was calculated for complete responders only and was defined as the time from documented initial complete response prior to initiation of subsequent systemic antilymphoma therapy until documented disease progression or death, whichever occurred earlier. Participants who had not progressed or died at the time of the analysis were censored at the date of last response assessment demonstrating no disease progression. Participants who changed treatment without evidence of disease progression were censored at the last assessment showing no progression prior to treatment change.

Time frame:
From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months.
Reported as:
Median · Months
K-M Estimate of Duration of Complete Response
MonthsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
K-M Estimate of Duration of Complete ResponseNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP · Log Rank · p = 0.2143 · Hazard ratio (hr): 0.776 · 95% CI 0.521 to 1.157HR was derived from COX model adjusting for the 3 stratification factors mentioned above.
SecondaryK-M Estimate of Time to Next Lymphoma Therapy (TTNLT)

Time to next lymphoma therapy was defined as the time from randomization to the time of treatment change for the next lymphoma treatment. Participants without treatment change were censored at date last known alive. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as treatment change for the next lymphoma therapy if the decision to treat and the location to be treated were determined prior to randomization.

Time frame:
From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
Reported as:
Median · Months
K-M Estimate of Time to Next Lymphoma Therapy (TTNLT)
MonthsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
K-M Estimate of Time to Next Lymphoma Therapy (TTNLT)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP · Log Rank · p = 0.3150 · Hazard ratio (hr): 1.167 · 95% CI 0.856 to 1.590HR is derived from Cox model
SecondaryPercentage of Participants Who Completed the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire

The completion rate for FACT-Lym assessments was judged by looking at the number of completed FACT-Lym assessments at each time point. The FACT-Lym was considered completed if at least 1 calculable score was present. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The FACT-Lym is a health related quality of life (HRQoL) questionnaire targeted to the management of chronic illness, predominantly within oncology and is considered an extension of the FACT-General questionnaire.

Time frame:
Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Completed the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire
Percentage of ParticipantsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Screening98.698.2
Midcycle = After Cycle 3, but before Cycle 487.086.3
End of Treatment (EoT) = 3-4 weeks after C676.179.6
Follow-Up Period: Week 3467.769.5
SecondaryPercentage of Participants Who Completed the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Health Related Quality of Life (HR-QoL) Questionnaire

The completion rate for EQ-5D assessments was judged by looking at the number of completed assessments at each time point. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored using the United Kingdom (UK) index ranges from -0.594 - 1, where 0 equates to death and 1 equates to full health -0.594 is considered 'worse than death'.

Time frame:
Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Completed the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Health Related Quality of Life (HR-QoL) Questionnaire
Percentage of ParticipantsLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Screening98.997.9
Midcycle87.086.3
End of Treatment (EoT)76.579.6
Follow-Up Period: Week 3468.169.1
SecondaryMean Change From Baseline in the FACT-Lym Physical Well-Being Subscale

The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The physical well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.

Time frame:
Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the FACT-Lym Physical Well-Being Subscale
Units on a ScaleLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Midcycle-0.7 ± 5.910.2 ± 5.40
C6 D1-0.0 ± 6.350.9 ± 6.02
EoT = 3-4 weeks after C61.5 ± 5.530.7 ± 5.72
Follow-Up Period: Week 342.8 ± 5.242.6 ± 5.55
SecondaryMean Change From Baseline in the FACT-Lym Additional Concerns Subscale

The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms such as pain, itching, night sweats,trouble sleeping, fatigue and trouble concentrating and concerns regarding lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The Additional Concerns subscale ranges from 0 to 60, where higher scores reflect better HRQoL.

Time frame:
Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the FACT-Lym Additional Concerns Subscale
Units on a ScaleLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Midcycle3.8 ± 10.334.1 ± 8.88
C6 D15.8 ± 11.115.2 ± 9.40
EoT = 3-4 weeks after C66.6 ± 10.114.5 ± 9.62
Follow-Up Period: Week 348.3 ± 10.616.5 ± 9.20
SecondaryMean Change From Baseline in the FACT-Lym Functional Well-Being Subscale

The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The functional well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL.

Time frame:
Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the FACT-Lym Functional Well-Being Subscale
Units on a ScaleLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Midcycle-0.5 ± 6.120.5 ± 5.84
C6 D10.0 ± 6.241.4 ± 5.63
EoT = 3-4 weeks after C61.0 ± 6.530.7 ± 6.71
Follow-Up Period: Week 342.3 ± 6.653.1 ± 6.17
SecondaryMean Change From Baseline in the FACT-Lym Trial Outcome Index (TOI)

The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). The FACT-Lym TOI is calculated by summing the Physical Well-being, Functional Well-being and Additional Concerns scores and has a range of 0 to 116. Higher scores reflect better HRQoL or fewer symptoms.

Time frame:
Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the FACT-Lym Trial Outcome Index (TOI)
Units on a ScaleLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Midcycle2.6 ± 18.264.6 ± 16.49
C6 D15.9 ± 19.857.5 ± 17.40
EoT = 3-4 weeks after C69.1 ± 18.515.8 ± 18.64
Follow-Up Period: Week 3413.5 ± 18.7412.2 ± 17.97
SecondaryMean Change From Baseline in the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Index Score

The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems". The instrument is scored as a single summary index using one of the available EQ-5D-3L value sets; in this study the UK scoring weights 9 were used. The UK index ranges from -0.594 to 1, where 0 equates to death and 1 equates to full health (-0.594 is considered 'worse than death').

Time frame:
Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Index Score
Units on a ScaleLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Midcycle0.08 ± 0.3080.08 ± 0.281
C6 D10.10 ± 0.3250.14 ± 0.330
EoT = 3-4 weeks after C60.10 ± 0.3090.06 ± 0.319
Follow-Up Period: Week 340.15 ± 0.2930.09 ± 0.311
SecondaryMean Change From Baseline in the EQ-5D-3L Visual Analogue Scale (VAS)

The EQ-5D-3L questionnaire includes a visual analogue scale which records the respondent's self-rated health on a vertical, 0-100 scale where 100 = "Best imaginable health state" and 0 = "Worst imaginable health state". Higher scores again indicate better HRQoL and positive change scores indicate that post screening values were higher than those observed at screening. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to "no problems", "some problems" and "extreme problems".

Time frame:
Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the EQ-5D-3L Visual Analogue Scale (VAS)
Units on a ScaleLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Midcycle4.0 ± 20.53.0 ± 18.2
C6 D16.0 ± 23.59.0 ± 24.5
EoT = 3-4 weeks after C68.0 ± 18.76.0 ± 21.5
Follow-Up Period: Week 3412.0 ± 20.29 ± 21.4

Adverse events

Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 86 months). SAEs and Other AEs were monitored from the participant's first dose of study treatment up to 28 days after their last dose of LEN/PBO or any component of R-CHOP including the optional 2 additional doses of rituximab; measured up to approximately 33 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide Plus R-CHOP (R2-CHOP)85/285 (29.8%)104/283 (36.7%)272/283 (96.1%)
Placebo Plus R-CHOP88/285 (30.9%)88/284 (31%)270/284 (95.1%)
Most frequent serious events
Showing 10 of 161
Most frequent serious events
EventLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
Febrile neutropeniaBlood and lymphatic system disorders31/28314/284
NeutropeniaBlood and lymphatic system disorders19/28313/284
ThrombocytopeniaBlood and lymphatic system disorders16/2831/284
PneumoniaInfections and infestations15/2839/284
PyrexiaGeneral disorders7/2839/284
AnaemiaBlood and lymphatic system disorders6/2836/284
DiarrhoeaGastrointestinal disorders6/2834/284
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/2833/284
Abdominal painGastrointestinal disorders4/2830/284
Atrial fibrillationCardiac disorders2/2834/284
Most frequent other events
Showing 10 of 40
Most frequent other events
EventLenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOP
NeutropeniaBlood and lymphatic system disorders183/283150/284
AnaemiaBlood and lymphatic system disorders127/28395/284
ConstipationGastrointestinal disorders92/28381/284
ThrombocytopeniaBlood and lymphatic system disorders68/28355/284
NauseaGastrointestinal disorders64/28366/284
PyrexiaGeneral disorders52/28340/284
Peripheral sensory neuropathyNervous system disorders51/28351/284
LeukopeniaBlood and lymphatic system disorders50/28350/284
FatigueGeneral disorders40/28350/284
DiarrhoeaGastrointestinal disorders49/28340/284

Baseline characteristics

The Intent-to-treat (ITT) population was defined as all participants who were randomized into the trial, regardless of whether they received study treatment or not.

Age, Continuous
Age, Continuous(Years)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
Mean62.5 ± 11.7263.9 ± 9.3563.2 ± 10.62
Age, Customized
Age, Customized(Participants)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
< 65138137275
≥ 65147148295
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
Female121142263
Male164143307
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
Hispanic or Latino141731
Not Hispanic or Latino270267537
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
White173183356
Asian10189190
Black or African American235
Other325
Not Collected or Reported6814
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
Mean1.780 ± 0.21671.775 ± 0.21011.777 ± 0.2132
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
0 = Fully Active129111240
1 = Restrictive but ambulatory104118222
2 = Ambulatory but unable to work5256108
Creatinine Clearance
Creatinine Clearance(mL/min)Lenalidomide Plus R-CHOP (R2-CHOP)Placebo Plus R-CHOPTotal
Mean92.08 ± 35.57690.19 ± 31.04091.14 ± 33.373

3 further baseline measures are reported on the registry.

08

Study locations

158 sites
  • Local Institution - 177
    Fayetteville, Arkansas 72703, United States
  • Local Institution - 136
    Orange, California 92868, United States
  • Local Institution - 127
    Sacramento, California 95817, United States
  • Local Institution - 169
    New Haven, Connecticut 06510, United States
  • Local Institution - 128
    Hollywood, Florida 33021, United States
  • McFarland Clinic
    Ames, Iowa 50010-3014, United States
  • Siouxland Hematology-Oncology Associates, LLP
    Sioux City, Iowa 51101-1733, United States
  • Local Institution - 143
    Fairway, Kansas 66205, United States
  • Local Institution - 158
    Shreveport, Louisiana 71103, United States
  • Center For Cancer And Blood Disorders
    Bethesda, Maryland 20817, United States
  • Local Institution - 101
    Minneapolis, Minnesota 55416, United States
  • Local Institution - 138
    Minneapolis, Minnesota 55455, United States
  • Local Institution - 112
    Rochester, Minnesota 55905, United States
  • Local Institution - 103
    Durham, North Carolina 27710, United States
  • Local Institution - 161
    Philadelphia, Pennsylvania 19111, United States
  • Local Institution - 951
    Dallas, Texas 75235, United States
  • Local Institution - 151
    Dallas, Texas 75390-9068, United States
  • Local Institution - 146
    Salt Lake City, Utah 84106, United States
  • Local Institution - 905
    Edmonds, Washington 98026, United States
  • Local Institution - 903
    Issaquah, Washington 98029, United States
  • Local Institution - 162
    Seattle, Washington 98104, United States
  • Local Institution - 904
    Seattle, Washington 98107, United States
  • Local Institution - 004
    Albury, New South Wales 2640, Australia
  • Local Institution - 008
    Clayton, Victoria 3168, Australia
  • Local Institution - 002
    Geelong, Victoria 3220, Australia
  • Local Institution - 003
    Frankston, 3199, Australia
  • Local Institution - 301
    Brussels, 1200, Belgium
  • Local Institution - 307
    Liege, 4000, Belgium
  • Local Institution - 305
    Roeselare, 8800, Belgium
  • Local Institution - 303
    Sint-Niklaas, 9100, Belgium
  • Local Institution - 368
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution - 373
    Surrey, British Columbia V3T 0H1, Canada
  • Local Institution - 366
    Saint John, New Brunswick E2L 3L6, Canada
  • Local Institution - 362
    Greenfield Park, Quebec J4V 2H1, Canada
  • Local Institution - 365
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution - 209
    Beijing, 100044, China
  • Local Institution - 206
    Beijing, 100142, China
  • Local Institution - 215
    Beijing, 100191, China
  • Local Institution - 200
    Beijing, 100730, China
  • Local Institution - 211
    Changchun, 130021, China
  • Local Institution - 210
    Chengdu, 610041, China
  • Local Institution - 213
    Chongqing, 400037, China
  • Local Institution - 202
    Fuzhou, 350001, China
  • Local Institution - 217
    Guangzhou, Guangdong, 510080, China
  • Local Institution - 204
    Hangzhou, 310003, China
  • Local Institution - 207
    Harbin, Heilongjiang, 150081, China
  • Local Institution - 205
    Nanjing, Jiangsu, 210009, China
  • Local Institution - 212
    Nanjing, 210029, China
  • Local Institution - 214
    Shanghai, 200032, China
  • Local Institution - 219
    Suzhu, 215006, China
  • Local Institution - 221
    Tianjin, 300060, China
  • Local Institution - 203
    Wuhan, 430030, China
  • Local Institution - 376
    Brno, 625 00, Czechia
  • Local Institution - 377
    Hradec Kralove, 500 05, Czechia
  • Local Institution - 379
    Olomouc, 775 20, Czechia
  • Local Institution - 380
    Prague 10, 100 34, Czechia
  • Local Institution - 378
    Praha, 128 08, Czechia
  • Local Institution - 576
    Bayonne, 64109, France
  • Local Institution - 585
    Bordeaux, 33076, France
  • Local Institution - 583
    Montpellier, 34295, France
  • Local Institution - 582
    Paris, 75010, France
  • Local Institution - 588
    Pessac Cedex, 33604, France
  • Local Institution - 587
    Toulose, 31059, France
  • Local Institution - 581
    Vandoeuvre les Nancy, 54511, France
  • Local Institution - 893
    Dublin 4, 4, Ireland
  • Local Institution - 894
    Galway, ST46QG, Ireland
  • Local Institution - 273
    Beer-Sheva, 84101, Israel
  • Local Institution - 274
    Haifa, 31096, Israel
  • Local Institution - 272
    Jerusalem, 91120, Israel
  • Local Institution - 275
    Kfar-Saba, 44281, Israel
  • Local Institution - 277
    Petach Tikva, 49100, Israel
  • Local Institution - 278
    Tel-Aviv, 64239, Israel
  • Local Institution - 270
    Zerifin, 70300, Israel
  • Local Institution - 690
    Terni, Umbria 05100, Italy
  • Local Institution - 659
    Allessandria, 15100, Italy
  • Local Institution - 658
    Brescia, 25123, Italy
  • Local Institution - 674
    Cuneo, 12100, Italy
  • Local Institution - 664
    Firenze, 50134, Italy
  • Local Institution - 652
    Genova, 16132, Italy
  • Local Institution - 667
    Ivrea, 10015, Italy
  • Local Institution - 684
    Meldola, 47014, Italy
  • Local Institution - 666
    Milano, 20132, Italy
  • Local Institution - 653
    Milano, 20133, Italy
  • Local Institution - 676
    Milano, 20162, Italy
  • Local Institution - 657
    Napoli, Campania, 80131, Italy
  • Local Institution - 655
    Novara, 28100, Italy
  • Local Institution - 685
    Padova, 35128, Italy
  • Local Institution - 686
    Pagani, 84016, Italy
  • Local Institution - 651
    Pavia, 27100, Italy
  • Local Institution - 679
    Ravenna, 48121, Italy
  • Local Institution - 668
    Reggio Emilia, 42100, Italy
  • Local Institution - 683
    Rimini, 47900, Italy
  • Local Institution - 689
    Roma, 00128, Italy
  • Local Institution - 694
    Roma, 00161, Italy
  • Local Institution - 673
    Roma, 00189, Italy
  • Local Institution - 656
    Rome, 00152, Italy
  • Local Institution - 671
    Torino, 01012, Italy
  • Local Institution - 662
    Torino, 10126, Italy
  • Local Institution - 681
    Tricase, 73039, Italy
  • Local Institution - 692
    Udine, 33100, Italy

Showing the first 100 of 158 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nowakowski GS, Chiappella A, Witzig TE, Spina M, Gascoyne RD, Zhang L, Flament J, Repici J, Vitolo U. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016 Jul;12(13):1553-63. doi: 10.2217/fon-2016-0130. Epub 2016 Apr 18. PubMed 27089170 ↗
  • Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Ozcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mocikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021 Apr 20;39(12):1317-1328. doi: 10.1200/JCO.20.01366. Epub 2021 Feb 23. PubMed 33621109 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Mar 2019, 48 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 48 months is close to that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2014
First posted
Nov 6, 2014
StartActual
Feb 17, 2015
Primary completionActual
Mar 15, 2019
CompletionActual
Jul 28, 2022
Results first posted
Mar 30, 2020
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02285062
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 6, 2014
Start date
Feb 17, 2015
Primary completion
Mar 15, 2019
Completion
Jul 28, 2022
Results posted
Mar 30, 2020
Last update
Jun 22, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion